Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG

Video

“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.

In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.

Related Videos
Dr. Kyle A. Richards in an interview with Urology Times
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
stethoscope on laptop keyboard
Randie White, MD, answers a question during a Zoom video interview
Udit Singhal, MD, answers a question during a Zoom video interview
Hospital hallway | Image Credit: © Paolese - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.